124 related articles for article (PubMed ID: 8993003)
1. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.
Yang G; Mizuno MT; Hellström KE; Chen L
J Immunol; 1997 Jan; 158(2):851-8. PubMed ID: 8993003
[TBL] [Abstract][Full Text] [Related]
2. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
[TBL] [Abstract][Full Text] [Related]
3. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.
Yang G; Hellström KE; Mizuno MT; Chen L
J Immunol; 1995 Oct; 155(8):3897-903. PubMed ID: 7561096
[TBL] [Abstract][Full Text] [Related]
4. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
5. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
Townsend SE; Su FW; Atherton JM; Allison JP
Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
[TBL] [Abstract][Full Text] [Related]
6. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
[TBL] [Abstract][Full Text] [Related]
7. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE
Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958
[TBL] [Abstract][Full Text] [Related]
8. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
Prell RA; Kerkvliet NI
J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803
[TBL] [Abstract][Full Text] [Related]
9. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
10. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
[TBL] [Abstract][Full Text] [Related]
11. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815.
Brichard VG; Warnier G; Van Pel A; Morlighem G; Lucas S; Boon T
Eur J Immunol; 1995 Mar; 25(3):664-71. PubMed ID: 7705394
[TBL] [Abstract][Full Text] [Related]
12. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
Dye ES
J Immunol; 1986 Feb; 136(4):1510-5. PubMed ID: 3080526
[TBL] [Abstract][Full Text] [Related]
13. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
Liu A; Hu P; Khawli LA; Epstein AL
J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
[TBL] [Abstract][Full Text] [Related]
14. Requirements for CD28-dependent T cell-mediated cytotoxicity.
Azuma M; Cayabyab M; Phillips JH; Lanier LL
J Immunol; 1993 Mar; 150(6):2091-101. PubMed ID: 8383716
[TBL] [Abstract][Full Text] [Related]
15. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
Gajewski TF; Fallarino F; Uyttenhove C; Boon T
J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
[TBL] [Abstract][Full Text] [Related]
16. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
17. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
[TBL] [Abstract][Full Text] [Related]
18. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors.
Liu B; Podack ER; Allison JP; Malek TR
J Immunol; 1996 Feb; 156(3):1117-25. PubMed ID: 8557987
[TBL] [Abstract][Full Text] [Related]
19. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
[TBL] [Abstract][Full Text] [Related]
20. Costimulation provided by DNA immunization enhances antitumor immunity.
Corr M; Tighe H; Lee D; Dudler J; Trieu M; Brinson DC; Carson DA
J Immunol; 1997 Nov; 159(10):4999-5004. PubMed ID: 9366427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]